Stockreport

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Pulse Biosciences, Inc  (PLSE) 
Last pulse biosciences, inc earnings: 11/7 03:42 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.pulsebiosciences.com
PDF HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pu [Read more]